Taken together, our findings revealed that legumain is involved in the pathogenesis of AKI via regulating the degradation of major ferroptosis-protective factor GPX4, suggesting legumain as a therapeutic target for the treatment of AKI. This evidence concerns the gene GPX4 and acute kidney injury.